Given the broad distribution of EGFR expression in many healthy human tissues, EGFR-targeting strategies with improved tumor specificity are required to be able to improve CAR T cell potency without simultaneously enhancing on-target/off-tumor toxicity. The gene discussed is EGFR; the disease is neoplasm.